J&J's Janssen Reports Results Of 2 Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine, Cabotegravir Showed Comparable Safety, Efficacy To Daily Oral HIV Therapy
Benzinga Newsdesk